doi: 10.1007/BF01778335.
Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse
Affiliations
- PMID: 8548401
- DOI: 10.1007/BF01778335
Item in Clipboard
Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse
Inflamm Res.
1995 Aug.
No abstract available
Similar articles
-
Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus.Arthritis Rheum. 1994 Feb;37(2):289-97. doi: 10.1002/art.1780370219. Arthritis Rheum. 1994. PMID: 8129783
-
Cyclosporine, FK-506, rapamycin, and other immunomodulators.Rheum Dis Clin North Am. 1996 Feb;22(1):133-54. doi: 10.1016/s0889-857x(05)70266-0. Rheum Dis Clin North Am. 1996. PMID: 8907069 Review.
-
Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.Transplant Proc. 1996 Dec;28(6):3270-1. Transplant Proc. 1996. PMID: 8962270 No abstract available.
-
Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.Transplant Proc. 1994 Oct;26(5):3025-7. Transplant Proc. 1994. PMID: 7940952 No abstract available.
-
Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.Transplant Proc. 1995 Feb;27(1):33-6. Transplant Proc. 1995. PMID: 7879019 Review. No abstract available.
Cited by
-
Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus.Front Pharmacol. 2019 Feb 6;10:82. doi: 10.3389/fphar.2019.00082. eCollection 2019. Front Pharmacol. 2019. PMID: 30787878 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical